Systemic administration of low-dose naltrexone increases bone mass due to blockade of opioid growth factor receptor signaling in mice osteoblasts.

top of page

RRM Academy

Life Sci. 2019 May 1;224:232-240. doi: 10.1016/j.lfs.2019.03.069. Epub 2019 Mar 28.

Systemic administration of low-dose naltrexone increases bone mass due to blockade of opioid growth factor receptor signaling in mice osteoblasts.

Tanaka K, Kondo H, Hamamura K, Togari A

Source:

https://doi.org/10.1016/j.lfs.2019.03.069

PubMed:

Research Library references a growing number of academic resources related to restorative reproductive medicine.

bottom of page